JP5642710B2 - マイコプラズマ・ガリセプティカム製剤 - Google Patents

マイコプラズマ・ガリセプティカム製剤 Download PDF

Info

Publication number
JP5642710B2
JP5642710B2 JP2011548121A JP2011548121A JP5642710B2 JP 5642710 B2 JP5642710 B2 JP 5642710B2 JP 2011548121 A JP2011548121 A JP 2011548121A JP 2011548121 A JP2011548121 A JP 2011548121A JP 5642710 B2 JP5642710 B2 JP 5642710B2
Authority
JP
Japan
Prior art keywords
strain
mycoplasma
mycoplasma gallisepticum
birds
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011548121A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012515552A5 (https=
JP2012515552A (ja
Inventor
クレヴェン，スタンレー，エイチ．
ファーガソン，ナオラ，エム．
Original Assignee
ユニバーシティ オブ ジョージア リサーチ ファンデーション，インコーポレーテッド
ユニバーシティ オブ ジョージア リサーチ ファンデーション，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ ジョージア リサーチ ファンデーション，インコーポレーテッド, ユニバーシティ オブ ジョージア リサーチ ファンデーション，インコーポレーテッド filed Critical ユニバーシティ オブ ジョージア リサーチ ファンデーション，インコーポレーテッド
Publication of JP2012515552A publication Critical patent/JP2012515552A/ja
Publication of JP2012515552A5 publication Critical patent/JP2012515552A5/ja
Application granted granted Critical
Publication of JP5642710B2 publication Critical patent/JP5642710B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/35—Mycoplasma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/87—Mycoplasma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2011548121A 2009-01-22 2010-01-22 マイコプラズマ・ガリセプティカム製剤 Active JP5642710B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14647209P 2009-01-22 2009-01-22
US61/146,472 2009-01-22
PCT/US2010/021749 WO2010085611A2 (en) 2009-01-22 2010-01-22 Mycoplasma gallisepticum formulation

Publications (3)

Publication Number Publication Date
JP2012515552A JP2012515552A (ja) 2012-07-12
JP2012515552A5 JP2012515552A5 (https=) 2012-11-01
JP5642710B2 true JP5642710B2 (ja) 2014-12-17

Family

ID=42356391

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011548121A Active JP5642710B2 (ja) 2009-01-22 2010-01-22 マイコプラズマ・ガリセプティカム製剤

Country Status (9)

Country Link
US (1) US8668912B2 (https=)
EP (1) EP2389433B1 (https=)
JP (1) JP5642710B2 (https=)
KR (1) KR101715159B1 (https=)
CN (1) CN102292432B (https=)
BR (1) BRPI1006947B1 (https=)
CA (1) CA2749213C (https=)
MX (1) MX2011007732A (https=)
WO (1) WO2010085611A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2943219T4 (pl) * 2012-09-10 2022-08-22 Susan Szathmary Szczepionka do zapobiegania zakażeniu mykoplazmalnemu u ptactwa wodnego
CN106967829A (zh) * 2017-05-18 2017-07-21 隋兆峰 一种鉴别mg 6/85株的套式pcr检测方法
CN110218808B (zh) * 2019-06-28 2021-07-13 华中农业大学 滑液囊支原体和鸡毒支原体的四重pcr检测试剂盒
CN119816588A (zh) * 2022-04-06 2025-04-11 乔治亚大学研究基金公司 鸡毒支原体活疫苗
US20260014240A1 (en) * 2022-07-20 2026-01-15 University Of Connecticut Rationally designed mycoplasma gallisepticum subunit vaccine
CN118078972B (zh) * 2024-03-07 2024-10-22 佛山大学 一种鹅源鸡毒支原体灭活疫苗及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196514A (en) 1990-03-06 1993-03-23 The University Of Georgia Research Foundation, Inc. Method of detecting mycoplasma infection in poultry and compositions therefor
WO1993001276A1 (en) 1991-07-12 1993-01-21 Smithkline Beecham Corporation Continuous cell line and vaccine against avian coccidia
US7217420B2 (en) * 2002-07-13 2007-05-15 The University Of Georgia Research Foundation, Inc. Mycoplasma gallisepticum formulation
US7785822B2 (en) 2002-08-27 2010-08-31 University Of Georgia Research Foundation, Inc. Assays for the detection of biliverdin in birds and reptiles
US20070178115A1 (en) 2005-08-15 2007-08-02 Tang De-Chu C Immunization of avians by administration of non-replicating vectored vaccines

Also Published As

Publication number Publication date
HK1161289A1 (zh) 2012-08-24
BRPI1006947A2 (pt) 2016-10-04
CA2749213A1 (en) 2010-07-29
BRPI1006947B1 (pt) 2020-02-04
WO2010085611A2 (en) 2010-07-29
CA2749213C (en) 2017-08-15
KR20110123748A (ko) 2011-11-15
CN102292432B (zh) 2013-05-22
KR101715159B1 (ko) 2017-03-10
US8668912B2 (en) 2014-03-11
EP2389433A2 (en) 2011-11-30
WO2010085611A3 (en) 2010-11-25
CN102292432A (zh) 2011-12-21
MX2011007732A (es) 2011-11-04
EP2389433B1 (en) 2015-11-25
US20120021005A1 (en) 2012-01-26
JP2012515552A (ja) 2012-07-12
EP2389433A4 (en) 2012-10-17

Similar Documents

Publication Publication Date Title
CN101309701A (zh) 治疗犬流感的疫苗和方法
JP5642710B2 (ja) マイコプラズマ・ガリセプティカム製剤
CN119816588A (zh) 鸡毒支原体活疫苗
KR20120016282A (ko) 마이코플라스마　하이오뉴모니에의 온도 감수성 백신 균주 및 그의 용도
Liu et al. Efficacy of Newcastle disease LaSota vaccine-induced hemagglutination inhibition antibodies against challenges with heterologous virulent strains of genotypes VII and IX
Perelman et al. Use of controlled exposure as a novel method for reovirus arthritis/tenosynovitis prevention. A preliminary report
Haddas Newcastle disease virus
CN116348595A (zh) 传染性支气管炎病毒株dmv1639的减毒分离株
MXPA05000467A (es) Formulacion de micoplasma gallisepticum.
JP2018526454A (ja) ブタコレラ菌−ネズミチフス菌ワクチン
JP2006503863A (ja) トリ吸収不良症候群に関与するウイルスを含有するワクチンおよびその投与法
KR101360112B1 (ko) 공기전파가 가능한 신규한 ｈ９ｎ２형 저병원성 조류인플루엔자 바이러스 균주 및 그로부터 유래된 백신
US20250186512A1 (en) Live mycoplasma synoviae vaccine
Liu et al. A newly developed temperature-sensitive Mycoplasma synoviae live attenuated strain prevents pathological lesions of the respiratory and reproductive tracts in chickens caused by a wild-type M. synoviae strain
CN110713987A (zh) 一种重组基因vii型新城疫病毒毒株及其疫苗组合物、制备方法及应用
HK1161289B (en) Mycoplasma gallisepticum formulation
Jayasinghe et al. Erysipelas in Wild Birds
GOMAA et al. EVALUATION OF SOME VACCINATION PROGRAMS AGAINST NEWCASTLE DISEASE VIRUS IN EXPERIMENTALLY CHALLENGED BROILER CHICKENS
Raheem et al. Continental Veterinary Journal
Armour An evaluation of the molecular epidemiology and transmission of avian mycoplasma genotypes in commercial poultry
Siddiqui et al. A comprehensive overview of infectious bursal disease, a major threat to poultry health and production
DH et al. HAEM0PHILUS PARAEALLINARUM (INFECTI0US C0RYZA) SER0TYPES AND VARIANTS...... 98
Abbassi et al. The following abstracts are from the oral and poster sessions presented at the Poultry Medicine Section of the 1999 AVMA Annual Convention in New Orleans, La, July 10-July 14, 1999. Abstracts for the Poultry Medicine Section

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140901

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141014

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141029

R150 Certificate of patent or registration of utility model

Ref document number: 5642710

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250